Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04609878
Other study ID # D5982C00007
Secondary ID 2023-505787-1120
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 15, 2020
Est. completion date March 21, 2025

Study information

Verified date June 2024
Source AstraZeneca
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Email information.center@astrazeneca.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care


Description:

This is a randomized, double-blind, double dummy, parallel group, multicenter 24 to 52 week variable length study to assess the efficacy and safety of budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler (MDI) relative to budesonide and formoterol fumarate MDI and Symbicort® pressurized MDI in adult and adolescent participants with inadequately controlled asthma. Approximately 2200 participants will be randomized globally.


Recruitment information / eligibility

Status Recruiting
Enrollment 2200
Est. completion date March 21, 2025
Est. primary completion date March 21, 2025
Accepts healthy volunteers No
Gender All
Age group 12 Years to 80 Years
Eligibility Inclusion Criteria: 1. 12 to 80 years of age, male and female, BMI <40 kg/m2; females must be not of childbearing potential or using a form of highly effective birth control. 2. Documented history of physician-diagnosed asthma > and/or = 1 year prior to V1. 3. Regularly using a stable daily ICS/LABA regimen (including a stable ICS dose) with medium-to-high ICS doses for at least 4 weeks prior to V1. 4. ACQ-7 total score =1.5 at Visits 1, 3, and 5 (pre-randomization). 5. FEV1 % (assessed as an average of the 60 and 30 minute pre-dose assessments) predicted normal at V1, 2, 3, 4, and 5 (pre-randomization) - Participants = 18 years of age: < 80% - Participants 12 to <18 years of age: < 90% 6. FEV1 post-albuterol at V2 or V3 (if repeat needed). - Participants > and/or = 18 years of age: Increase > and/or = 12% and > and/or = 200 mL. - Participants 12 to <18 years of age: Increase =12% either in the 12 months prior to Visit 1 or at Visit 2, or at Visit 3. - Note: Even if there is documented history of reversibility, all participants must be assessed for reversibility at Visit 2 (and Visit 3, if reversibility is not demonstrated at Visit 2) to provide reversibility baseline data for characterization. 7. Willing and, in the opinion of the Investigator, able to adjust current asthma therapy, as required by the protocol. 8. Demonstrate acceptable MDI/pMDI administration technique. 9. Received no asthma medication other than run-in BFF MDI BID and albuterol as needed during screening (except for allowed medications as defined in Table 9 and systemic corticosteroid or ICS for the treatment of an asthma exacerbation). 10. eDiary 14-day compliance =70% during screening (defined as completing the daily eDiary for any 10 mornings and any 10 evenings and answering "Yes" to taking 2 puffs of run-in BFF MDI for any 10 mornings and 10 evenings in the last 14 days prior to randomization). 11. No respiratory infection in the 4 weeks prior to randomization, or asthma exacerbation treated with systemic corticosteroid and/or additional ICS treatment in the 4 weeks prior to randomization. Exclusion Criteria: 1. Completed treatment for respiratory infection or asthma exacerbation with systemic corticosteroids within 4 weeks of V1. 2a. Participants where, in the opinion of the Investigator, treatment with biological therapy for asthma would be appropriate. 2b. Any marketed or investigational biologics within 3 months or 5 half-lives of V1, whichever is longer and must not be used during study duration. 3. Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking <6 months prior to V1 (including all forms of tobacco, e-cigarettes or other vaping devices, and marijuana). 4. Current evidence of Chronic Obstructive Pulmonary Disease (COPD). 5a. Oral and IV corticosteroid use (any dose) within 4 weeks of V1. 5b. Use of systemic corticosteroids for any other reason except for the acute treatment of severe asthma exacerbation is prohibited for the duration of the study. 5c. Depot corticosteroid use for any reason within 3 months of V1. 6. Use of Long-Acting Muscarinic Antagonist (LAMA), either alone or as part of an inhaled combination therapy, in the 12 weeks prior to V1. 7. Use of oral beta2-agonist within 3 months of V1. 8. Use of any immunomodulators or immunosuppressive medication within 3 months or 5 half-lives, whichever is longer, and must not be used during the study duration. 9. Narrow angle glaucoma not adequately treated and/or change in vision that may be relevant, in the opinion of the Investigator, within 3 months of Visit 1. 10. Life-threatening asthma defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s). 11. Hospitalization for asthma within 2 months of Visit 1. 12. Known history of drug or alcohol abuse within 12 months of Visit 1. 13. Regular use of a nebulizer or a home nebulizer for receiving asthma medications. 14. Using any herbal products by inhalation or nebulizer within 4 weeks of Visit 1 and does not agree to stop during the study duration. 15. Participation in another clinical study with a study intervention administered in the last 30 days or 5 half-lives, whichever is longer. Any other study intervention that is not identified in the protocol is prohibited for use during study duration. 16. Participants with a known hypersensitivity to beta2-agonists, corticosteroids, anticholinergics, or any component of the MDI or pMDI. 17. Study Investigators, sub-Investigators, coordinators, and their employees or immediate family members. 18. For women only - currently pregnant (confirmed with positive highly sensitive pregnancy test), breast-feeding, or planned pregnancy during the study or not using acceptable contraception measures, as judged by the Investigator. Please refer to the study protocol for the complete inclusion and exclusion criteria list.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BGF MDI 320/28.8/9.6 µg
Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
BGF MDI 320/14.4/9.6 µg
Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
BFF MDI 320/9.6 µg
Budesonide and formoterol fumarate metered dose inhaler
BFF pMDI 320/9 µg
Budesonide/formoterol fumarate pressurized metered dose inhaler

Locations

Country Name City State
Argentina Research Site Buenos Aires
Argentina Research Site Buenos Aires
Argentina Research Site Buenos Aires
Argentina Research Site Caba
Argentina Research Site Caba
Argentina Research Site Caba
Argentina Research Site Ciudad Autonoma de Buenos Aire
Argentina Research Site Ciudad de Buenos Aires
Argentina Research Site Córdoba
Argentina Research Site Florida
Argentina Research Site Mar del Plata
Argentina Research Site Mendoza
Argentina Research Site Ranelagh
Argentina Research Site Rosario
Argentina Research Site Rosario
Argentina Research Site San Fernando
Australia Research Site Darlinghurst
Australia Research Site Melbourne
Australia Research Site South Brisbane
Australia Research Site Spearwood
Belgium Research Site Bruxelles
Belgium Research Site Edegem
Belgium Research Site Liège
Belgium Research Site Namur
Belgium Research Site Roeselare
Bulgaria Research Site Dupnitsa
Bulgaria Research Site Dupnitsa
Bulgaria Research Site Haskovo
Bulgaria Research Site Kozloduy
Bulgaria Research Site Lovech
Bulgaria Research Site Pazardzhik
Bulgaria Research Site Petrich
Bulgaria Research Site Pleven
Bulgaria Research Site Pleven
Bulgaria Research Site Ruse
Bulgaria Research Site Ruse
Bulgaria Research Site Sevlievo
Bulgaria Research Site Sliven
Bulgaria Research Site Smolyan
Bulgaria Research Site Sofia
Bulgaria Research Site Sofia
Bulgaria Research Site Sofia
Bulgaria Research Site Sofia
Bulgaria Research Site Sofia
Bulgaria Research Site Stara Zagora
Bulgaria Research Site Stara Zagora
Bulgaria Research Site Varna
Bulgaria Research Site Veliko Tarnovo
Bulgaria Research Site Vidin
Bulgaria Research Site Vratsa
Canada Research Site Ajax Ontario
Canada Research Site Burlington Ontario
Canada Research Site Calgary Alberta
Canada Research Site Edmonton Alberta
Canada Research Site Edmonton Alberta
Canada Research Site Hamilton Ontario
Canada Research Site Kelowna British Columbia
Canada Research Site London Ontario
Canada Research Site Lower Sackville Nova Scotia
Canada Research Site Mount Pearl Newfoundland and Labrador
Canada Research Site Newmarket Ontario
Canada Research Site Niagara Falls Ontario
Canada Research Site Niagara Falls Ontario
Canada Research Site Quebec
Canada Research Site Quebec
Canada Research Site Quebec
Canada Research Site Sherwood Park Alberta
Canada Research Site Toronto Ontario
Canada Research Site Toronto Ontario
Canada Research Site Toronto Ontario
Canada Research Site Vancouver British Columbia
Canada Research Site Vancouver British Columbia
Canada Research Site Winnipeg Manitoba
Canada Research Site Winnipeg Manitoba
Chile Research Site Curico
Chile Research Site Quillota
Chile Research Site Santiago
Chile Research Site Santiago
Chile Research Site Santiago
Chile Research Site Santiago
Chile Research Site Santiago
Chile Research Site Talca
Chile Research Site Temuco
Chile Research Site Viña del Mar
Chile Research Site Viña del Mar
Denmark Research Site Aalborg
Denmark Research Site Hjørring
Denmark Research Site Hvidovre
Denmark Research Site Vejle
Hungary Research Site Balassagyarmat
Hungary Research Site Budapest
Hungary Research Site Budapest
Hungary Research Site Edelény
Hungary Research Site Encs
Hungary Research Site Farkasgyepü
Hungary Research Site Gödöllo
Hungary Research Site Hajdúnánás
Hungary Research Site Hódmezovásárhely
Hungary Research Site Komárom
Hungary Research Site Pécs
Hungary Research Site Siófok
Hungary Research Site Szeged
Hungary Research Site Szeged
Hungary Research Site Szigetvár
India Research Site Ahmedabad
India Research Site Aligarh
India Research Site Bangalore
India Research Site Belagavi
India Research Site Bengaluru
India Research Site Coimbatore
India Research Site Dehradun
India Research Site Gurgaon
India Research Site Hyderabad
India Research Site Jaipur
India Research Site Jaipur
India Research Site Mohali
India Research Site Mumbai
India Research Site Nagpur
India Research Site New Delhi
India Research Site New Delhi
India Research Site New Delhi
India Research Site Noida
India Research Site Thane
India Research Site Vishakhapatnam
Italy Research Site Bari
Italy Research Site Battipaglia
Italy Research Site Biancavilla
Italy Research Site Casatenovo
Italy Research Site Catanzaro
Italy Research Site Cona
Italy Research Site Firenze
Italy Research Site Garbagnate Milanese
Italy Research Site Milano
Italy Research Site Monserrato
Italy Research Site Napoli
Italy Research Site Napoli
Italy Research Site Pisa
Italy Research Site Roma
Italy Research Site Roma
Italy Research Site Salerno
Italy Research Site Sassari
Japan Research Site Chino-shi
Japan Research Site Chuo-ku
Japan Research Site Chuo-ku
Japan Research Site Chuo-ku
Japan Research Site Chuo-ku
Japan Research Site Fukui-shi
Japan Research Site Fukuoka-shi
Japan Research Site Fukuoka-shi
Japan Research Site Fukuoka-shi
Japan Research Site Habikino-shi
Japan Research Site Hamamatsu-shi
Japan Research Site Higashiibaraki-gun
Japan Research Site Himeji-shi
Japan Research Site Hiroshima-shi, Naka-ku
Japan Research Site Hitachinaka-shi
Japan Research Site Ikoma-shi
Japan Research Site Kagoshima-shi
Japan Research Site Kanazawa-shi
Japan Research Site Kishiwada-shi
Japan Research Site Kitakyusyu
Japan Research Site Kiyose-shi
Japan Research Site Kokubunji-shi
Japan Research Site Kyoto-shi
Japan Research Site Kyoto-shi
Japan Research Site Meguro-ku
Japan Research Site Miyazaki-shi
Japan Research Site Nagaoka-shi
Japan Research Site Nagoya-shi
Japan Research Site Nankoku-shi
Japan Research Site Obihiro
Japan Research Site Oita-shi
Japan Research Site Omuta-shi
Japan Research Site Osaka-shi
Japan Research Site Osaka-shi
Japan Research Site Osaka-shi
Japan Research Site Saga-shi
Japan Research Site Sakaide-shi
Japan Research Site Sapporo-shi
Japan Research Site Sapporo-shi
Japan Research Site Setagaya-ku
Japan Research Site Setagaya-ku
Japan Research Site Shibuya-ku
Japan Research Site Shimotsuga-gun
Japan Research Site Shinagawa-ku
Japan Research Site Shinagawa-ku
Japan Research Site Shinjuku-ku
Japan Research Site Shinjuku-ku
Japan Research Site Shizuoka
Japan Research Site Takarazuka-shi
Japan Research Site Tanabe-shi
Japan Research Site Toon-shi
Japan Research Site Toshima-ku
Japan Research Site Toshima-ku
Japan Research Site Toshima-ku
Japan Research Site Toyama-shi
Japan Research Site Tsuchiura-shi
Japan Research Site Utsunomiya-shi
Japan Research Site Yanagawa-shi
Japan Research Site Yokohama-shi
Japan Research Site Yokohama-shi
Japan Research Site Yokohama-shi
Japan Research Site Yokohama-shi
Japan Research Site Yokohama-shi
Korea, Republic of Research Site Cheongju-si
Korea, Republic of Research Site Gangwon-do
Korea, Republic of Research Site Jeonju-si
Korea, Republic of Research Site Seongnam-si
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Suwon-si
Korea, Republic of Research Site Uijeongbu
Korea, Republic of Research Site Ulsan
Netherlands Research Site Deventer
Netherlands Research Site Eindhoven
Netherlands Research Site Heerlen
Netherlands Research Site Nijmegen
Netherlands Research Site Zutphen
New Zealand Research Site Auckland
New Zealand Research Site Auckland
New Zealand Research Site Grafton
New Zealand Research Site Nawton
New Zealand Research Site Nelson
New Zealand Research Site Rotorua
New Zealand Research Site Wellington
Peru Research Site Cusco
Peru Research Site Lima
Peru Research Site Lima
Peru Research Site Lima
Peru Research Site Lima
Peru Research Site Lima
Peru Research Site Lima
Peru Research Site Lima
Peru Research Site Piura
Philippines Research Site Baguio
Philippines Research Site Baguio City
Philippines Research Site Caloocan City
Philippines Research Site Davao City
Philippines Research Site Davao City
Philippines Research Site Iloilo City
Philippines Research Site Iloilo City
Philippines Research Site Las Pinas
Philippines Research Site Lipa City
Philippines Research Site Los Baños
Philippines Research Site Manila
Philippines Research Site Manila
Philippines Research Site Marilao
Philippines Research Site Pasig City
Philippines Research Site Quezon City
Philippines Research Site Quezon City
Philippines Research Site Quezon City
Poland Research Site Bialystok
Poland Research Site Bialystok
Poland Research Site Bydgoszcz
Poland Research Site Czestochowa
Poland Research Site Karczew
Poland Research Site Katowice
Poland Research Site Kielce
Poland Research Site Krakow
Poland Research Site Kraków
Poland Research Site Kraków
Poland Research Site Lublin
Poland Research Site Piaseczno
Poland Research Site Poznan
Poland Research Site Poznan
Poland Research Site Poznan
Poland Research Site Poznan
Poland Research Site Poznan
Poland Research Site Poznan
Poland Research Site Rzeszow
Poland Research Site Rzeszów
Poland Research Site Rzeszów
Poland Research Site Sosnowiec
Poland Research Site Sosnowiec
Poland Research Site Strzelce Opolskie
Poland Research Site Szczecin
Poland Research Site Tarnów
Poland Research Site Wroclaw
Poland Research Site Wroclaw
Puerto Rico Research Site Caguas
Puerto Rico Research Site Guaynabo
Puerto Rico Research Site Ponce
Puerto Rico Research Site San Juan
Romania Research Site Bra?ov
Romania Research Site Brasov
Romania Research Site Brasov
Romania Research Site Bucharest
Romania Research Site Bucharest
Romania Research Site Ia?i
Romania Research Site Timisoara
Spain Research Site Barcelona
Spain Research Site Benalmádena
Spain Research Site Coslada
Spain Research Site Girona
Spain Research Site L'Hospitalet de Llobregat
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Málaga
Spain Research Site Marbella (Málaga)
Spain Research Site Pozuelo de Alarcón
Spain Research Site Santander
Spain Research Site Santiago De Compostela-Coruña
Spain Research Site Valencia
Spain Research Site Zaragoza
Spain Research Site Zaragoza
Taiwan Research Site Changhua
Taiwan Research Site Kaohsiung
Taiwan Research Site Kaohsiung
Taiwan Research Site Kaohsiung City
Taiwan Research Site New Taipei
Taiwan Research Site Taichung
Taiwan Research Site Taichung
Taiwan Research Site Tainan
Taiwan Research Site Taipei
Taiwan Research Site Taipei
Taiwan Research Site Taipei City
Taiwan Research Site Tao-Yuan
Thailand Research Site Bang Kra So
Thailand Research Site Bangkok
Thailand Research Site Bangkok
Thailand Research Site Bangkok
Thailand Research Site Hat Yai
Thailand Research Site Hatyai
Thailand Research Site Khon Kaen
Thailand Research Site Mae Rim
Thailand Research Site Muang
Thailand Research Site Muang
Thailand Research Site Mueang
Thailand Research Site Mueang Chanthaburi
United States Research Site Adairsville Georgia
United States Research Site Albuquerque New Mexico
United States Research Site Albuquerque New Mexico
United States Research Site Amarillo Texas
United States Research Site Anderson South Carolina
United States Research Site Atlanta Georgia
United States Research Site Austin Texas
United States Research Site Bangor Maine
United States Research Site Baytown Texas
United States Research Site Beaumont Texas
United States Research Site Bellevue Nebraska
United States Research Site Birmingham Alabama
United States Research Site Boerne Texas
United States Research Site Boston Massachusetts
United States Research Site Brandon Florida
United States Research Site Brick New Jersey
United States Research Site Bronx New York
United States Research Site Bronx New York
United States Research Site Brownsburg Indiana
United States Research Site Burlington Vermont
United States Research Site Champaign Illinois
United States Research Site Charlotte North Carolina
United States Research Site Charlotte North Carolina
United States Research Site Chesterfield Missouri
United States Research Site Chicago Illinois
United States Research Site Chicago Illinois
United States Research Site Chicago Illinois
United States Research Site Cincinnati Ohio
United States Research Site Cincinnati Ohio
United States Research Site Clarksville Tennessee
United States Research Site Clinton South Carolina
United States Research Site Colorado Springs Colorado
United States Research Site Columbia Maryland
United States Research Site Columbus Georgia
United States Research Site Covina California
United States Research Site Crowley Louisiana
United States Research Site Cudahy Wisconsin
United States Research Site Cypress Texas
United States Research Site Dallas Texas
United States Research Site Denver North Carolina
United States Research Site DuBois Pennsylvania
United States Research Site Duluth Georgia
United States Research Site East Providence Rhode Island
United States Research Site Edmond Oklahoma
United States Research Site El Paso Texas
United States Research Site Encinitas California
United States Research Site Fargo North Dakota
United States Research Site Flint Michigan
United States Research Site Franklin Tennessee
United States Research Site Fresno California
United States Research Site Gastonia North Carolina
United States Research Site Georgetown Texas
United States Research Site Georgetown Kentucky
United States Research Site Grants Pass Oregon
United States Research Site Greenville South Carolina
United States Research Site Hampton Georgia
United States Research Site Hannibal Missouri
United States Research Site Harlingen Texas
United States Research Site Houston Texas
United States Research Site Houston Texas
United States Research Site Houston Texas
United States Research Site Huntsville Alabama
United States Research Site Indianapolis Indiana
United States Research Site Kerrville Texas
United States Research Site Kingwood West Virginia
United States Research Site Lafayette Louisiana
United States Research Site Laguna Hills California
United States Research Site Lake Charles Louisiana
United States Research Site Lakewood Colorado
United States Research Site Lampasas Texas
United States Research Site Las Vegas Nevada
United States Research Site Lawrenceville Georgia
United States Research Site Lincoln Nebraska
United States Research Site Little Rock Arkansas
United States Research Site Long Beach California
United States Research Site Los Angeles California
United States Research Site Los Angeles California
United States Research Site Louisville Kentucky
United States Research Site Manassas Virginia
United States Research Site Maumee Ohio
United States Research Site Medford Oregon
United States Research Site Mesquite Texas
United States Research Site Miami Florida
United States Research Site Mission Hills California
United States Research Site Missoula Montana
United States Research Site Mooresville North Carolina
United States Research Site Morgantown West Virginia
United States Research Site New Hyde Park New York
United States Research Site New Windsor New York
United States Research Site New York New York
United States Research Site New York New York
United States Research Site Newport Beach California
United States Research Site Newport News Virginia
United States Research Site North Charleston South Carolina
United States Research Site Northridge California
United States Research Site Ocala Florida
United States Research Site Ogden Utah
United States Research Site Oklahoma City Oklahoma
United States Research Site Orangeburg South Carolina
United States Research Site Palm Harbor Florida
United States Research Site Pearland Texas
United States Research Site Phoenix Arizona
United States Research Site Phoenix Arizona
United States Research Site Pittsburgh Pennsylvania
United States Research Site Pittsburgh Pennsylvania
United States Research Site Plano Texas
United States Research Site Potomac Maryland
United States Research Site Raleigh North Carolina
United States Research Site Reading Pennsylvania
United States Research Site Red Oak Texas
United States Research Site Rincon Georgia
United States Research Site River Forest Illinois
United States Research Site Saint Louis Missouri
United States Research Site Saint Louis Missouri
United States Research Site Saint Petersburg Florida
United States Research Site San Antonio Texas
United States Research Site San Antonio Texas
United States Research Site San Antonio Texas
United States Research Site San Diego California
United States Research Site Saraland Alabama
United States Research Site Savannah Georgia
United States Research Site Scottdale Pennsylvania
United States Research Site Scottsdale Arizona
United States Research Site Smithfield Pennsylvania
United States Research Site Staten Island New York
United States Research Site Stockbridge Georgia
United States Research Site Stockton California
United States Research Site Sugar Land Texas
United States Research Site Sun City West Arizona
United States Research Site Tallahassee Florida
United States Research Site Tampa Florida
United States Research Site Thousand Oaks California
United States Research Site Toledo Ohio
United States Research Site Tomball Texas
United States Research Site Tomball Texas
United States Research Site Toms River New Jersey
United States Research Site Tucson Arizona
United States Research Site Tucson Arizona
United States Research Site Tulsa Oklahoma
United States Research Site Tulsa Oklahoma
United States Research Site Tyrone Georgia
United States Research Site Upland California
United States Research Site Valdosta Georgia
United States Research Site Waldorf Maryland
United States Research Site Waterbury Connecticut
United States Research Site West Des Moines Iowa
United States Research Site West Valley City Utah
United States Research Site Westminster California
United States Research Site Winter Garden Florida
Vietnam Research Site Ha Noi
Vietnam Research Site Hanoi
Vietnam Research Site Ho Chi Minh
Vietnam Research Site Ho Chi Minh
Vietnam Research Site Ho Chi Minh
Vietnam Research Site Ho Chi Minh City
Vietnam Research Site Hochiminh

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Vietnam,  Argentina,  Australia,  Belgium,  Bulgaria,  Canada,  Chile,  Denmark,  Hungary,  India,  Italy,  Japan,  Korea, Republic of,  Netherlands,  New Zealand,  Peru,  Philippines,  Poland,  Puerto Rico,  Romania,  Spain,  Taiwan,  Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 24 Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 24 24 Weeks
Primary Rate of severe asthma exacerbations Primary end point(s) of Pooled Studies D5982C00007 and D5982C00008: Rate of severe asthma exacerbations Up to 52 weeks
Secondary Change from baseline in morning pre-dose trough FEV1 at Week 24 Change from baseline in morning pre-dose trough FEV1 at Week 24 24 Weeks
Secondary Percentage of responders in Asthma Control Questionnaire (ACQ)-7 (=0.5 decrease equals response) at Week 24 Percentage of responders in ACQ-7 (=0.5 decrease equals response) at Week 24. Additional analysis will be conducted using pooled data from studies D5982C00007 and D5982C00008 24 weeks
Secondary Percentage of responders in ACQ-5 (=0.5 decrease equals response) at Week 24 Percentage of responders in ACQ-5 (=0.5 decrease equals response) at Week 24. Additional analysis will be conducted using pooled data from studies D5982C00007 and D5982C00008 24 Weeks
Secondary Percentage of responders in the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ +12) (=0.5 increase equals response) at Week 24 Percentage of responders in the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ(s) +12) (=0.5 increase equals response) at Week 24. Additional analysis will be conducted using pooled data from studies D5982C00007 and D5982C00008 24 weeks
Secondary Percentage of responders in the St. George's Respiratory Questionnaire (SGRQ) (=4.0 unit decrease equals response) at Week 24 Percentage of responders in the St. George's Respiratory Questionnaire (SGRQ) (=4.0 unit decrease equals response) at Week 24 24 Weeks
Secondary Onset of action on Day 1: Absolute change in FEV1 at 5 minutes on Day 1 Onset of action on Day 1: Absolute change in FEV1 at 5 minutes on Day 1 Day 1
Secondary Time to first severe asthma exacerbation Secondary end point(s) of Pooled Studies D5982C00007 and D5982C00008:
Time to first severe asthma exacerbation
Up to 52 Weeks
Secondary Rate of moderate/severe asthma exacerbations Secondary end point(s) of Pooled Studies D5982C00007 and D5982C00008:
Rate of moderate/severe asthma exacerbations
Up to 52 Weeks
Secondary Time to first moderate/severe asthma exacerbation Secondary end point(s) of Pooled Studies D5982C00007 and D5982C00008:
Time to first moderate/severe asthma exacerbation
Up to 52 Weeks
Secondary Rate of severe asthma exacerbations for participants with percent predicted FEV1 = 55% at baseline. Secondary end point(s) of Pooled Studies D5982C00007 and D5982C00008: Rate of severe asthma exacerbations for participants with percent predicted FEV1 = 55% at baseline. Up to 52 Weeks
Secondary Rate of severe asthma exacerbations for participants with = 1 severe exacerbation in the 12 months prior to Visit 1. Secondary end point(s) of Pooled Studies D5982C00007 and D5982C00008: Rate of severe asthma exacerbations for participants with = 1 severe exacerbation in the 12 months prior to Visit 1. Up to 52 Weeks
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device